The effect of feather bedding on childhood asthma: a randomised controlled trial

Not Applicable

Completed

• Conditions: Childhood asthma; Respiratory - Asthma

• Registration Number: ACTRN12609000394246
• Lead Sponsor: The Australian National University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-06-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

(1) aged 7 – 14 years;
(2) diagnosed with asthma;
(3) asthma symptoms that include wheeze; (4) four or more episodes of wheeze per year; or (5) have an episode of speech limiting wheeze in the past 12 months; (6) house dust mite (HDM) sensitised (wheal size of >= 3 mm to Der p 1 and/or Der f 1);
(7) sleep in a single bed; and (8) plan to remain in the study region for the next two years

Exclusion Criteria

(1) sensitised to feather (wheal size of < 3 mm to feather extract );
(2) sensitised to cat (wheal size of < 3 mm to cat pelt extract) if there is a cat at home;
(3) having a feather pillow or quilt on their bed when entering the study;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the proportion of children reporting four or more episodes of wheeze in the 12 months post intervention assessed by standarised questionnaire adminsitered at baseline and at 12 months[12 months];an episode of speech limiting wheeze in the 12 months post intervention assessed by standarised questionnaire adminsitered at baseline and at 12 months[12 months];reporting one or more episodes of nocturnal wheeze in the 12 months post intervention assessed by standarised questionnaire adminsitered at baseline and at 12 months[12 months]

Secondary Outcome Measures

Name	Time	Method
Spirometry at both baseline and endpoint including Foreced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), the FEV1/FVC ratio and the relative and absolute change in FEV1 after challenge[12 months];quality of life assessments using the Juniper Paediatric Quality of Life Questionnaire[12 months post intervention]